EUVIMEDEUVIMED entdecken
Open Access

Application Timing‐Dependent Impact of Donor Source on Outcomes After Allogeneic Hematopoietic Stem Cell Transplantation for Adult T‐Cell Leukemia/Lymphoma

Hidehiro Itonaga iD, Takuya Fukushima, Hiroyuki Muranushi iD, Nobuaki Nakano, Yoshitaka Inoue iD, Masahito Tokunaga iD, Takahiro Fukuda, Tetsuya Eto, Toshiro Kawakita, Takeharu Kato, Jun Ishikawa, Makoto Yoshimitsu und 9 weitere

Hematological Oncology · 2026

DOI: 10.1002/hon.70220 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Hematological Oncology, 2026. Verfasst von Hidehiro Itonaga und 20 weiteren Autor:innen. Beteiligte Einrichtung: Transfusion and Cell Therapy Unit, Nagasaki University Hospital, Nagasaki, Japan. Hauptthemen laut MEDLINE: Leukemia-Lymphoma, Adult T-Cell, Hematopoietic Stem Cell Transplantation, Tissue Donors. Die Arbeit nennt 58 Literaturangaben. Der Volltext ist frei in PubMed Central verfügbar. Gefördert von: Japan Society for the Promotion of Science, SGH Foundation, Japan Agency for Medical Research and Development.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Allogeneic hematopoietic stem cell transplantation (allo‐HSCT) is usually performed as a curative treatment for adult T‐cell leukemia/lymphoma (ATL), following first‐line chemotherapy. We conducted a nationwide retrospective study to examine the prognostic impact of donor sources based on transplantation application timings: human leukocyte antigen (HLA)‐matched related donor (MRD; n = 253), unrelated donor (URD; n = 656), unrelated cord blood (U‐CB; n = 599), and HLA‐haploidentical related donor with post‐transplant cyclophosphamide (PT‐CY; n = 166). In patients with the early application of allo‐HSCT (< 100 days from diagnosis), the multivariate analysis showed no significant difference in overall mortality (OM) among all donor sources. Regarding the middle timing of allo‐HSCT (100–179 days), the U‐CB group showed higher OM than the MRD group (hazard ratio [HR], 1.37; p = 0.013), while the URD and PT‐CY groups showed no significant difference in OM with the MRD group. Concerning the late timing of allo‐HSCT (180–270 days), the U‐CB (HR, 1.88; p = 0.005) and PT‐CY groups (HR, 1.90; p = 0.043) showed higher OM than the MRD group, whereas the URD group exhibited comparable OM to the MRD group. The present study demonstrated the differential impact of the graft source based on the timing of allo‐HSCT for ATL; therefore, it is important to select an optimal alternative donor based on application timing.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Leukemia-Lymphoma, Adult T-CellHematopoietic Stem Cell TransplantationTissue DonorsHumansFemaleMaleAdultMiddle AgedRetrospective StudiesTransplantation, HomologousAgedTime FactorsPrognosisTreatment OutcomeTransplantation ConditioningYoung AdultUnrelated Donors

Stichwörter der Autor:innen

adult T‐cell leukemia/lymphomaallogeneic hematopoietic stem cell transplantationdonor sourcetiming

Autor:innen und Institutionen

  • Transfusion and Cell Therapy Unit, Nagasaki University Hospital, Nagasaki, Japan.
  • Laboratory of Hematoimmunology, Department of Clinical Laboratory Sciences, School of Health Sciences, Faculty of Medicine, University of the Ryukyus, Ginowan, Japan.
  • Department of Hematology/Oncology and Transfusion and Hemapheresis Center, Kurashiki Central Hospital, Kurashiki, Kurashiki, Japan.
  • Department of Hematology, Imamura General Hospital, Kagoshima, Japan.
  • Department of Hematology, Kumamoto University Hospital, Kumamoto, Japan.
  • Department of Hematopoietic Stem Cell Transplantation, National Cancer Center Hospital, Tokyo, Japan.

ORCID-Profile: Hidehiro Itonaga, Hiroyuki Muranushi, Yoshitaka Inoue, Masahito Tokunaga, Yasuo Mori, Masuho Saburi, Youko Suehiro, Shigeo Fuji

Förderung

  • Japan Society for the Promotion of Science
  • SGH Foundation
  • Japan Agency for Medical Research and Development

Zitieren

APA

Itonaga, H., Fukushima, T., Muranushi, H., Nakano, N., Inoue, Y., Tokunaga, M., Fukuda, T., Eto, T., Kawakita, T., Kato, T., Ishikawa, J., Yoshimitsu, M., Uchida, N., Mori, Y., Saburi, M., Suehiro, Y., Ogata, M., Kanda, Y., Ishitsuka, K., …, & Fuji, S. (2026). Application Timing‐Dependent Impact of Donor Source on Outcomes After Allogeneic Hematopoietic Stem Cell Transplantation for Adult T‐Cell Leukemia/Lymphoma. Hematological Oncology. https://doi.org/10.1002/hon.70220

Vancouver

Itonaga H, Fukushima T, Muranushi H, Nakano N, Inoue Y, Tokunaga M, et al. Application Timing‐Dependent Impact of Donor Source on Outcomes After Allogeneic Hematopoietic Stem Cell Transplantation for Adult T‐Cell Leukemia/Lymphoma. Hematological Oncology. 2026. doi:10.1002/hon.70220

BibTeX
@article{Itonaga2026,
  author = {Itonaga, Hidehiro and Fukushima, Takuya and Muranushi, Hiroyuki and Nakano, Nobuaki and Inoue, Yoshitaka and Tokunaga, Masahito and Fukuda, Takahiro and Eto, Tetsuya and Kawakita, Toshiro and Kato, Takeharu and Ishikawa, Jun and Yoshimitsu, Makoto and Uchida, Naoyuki and Mori, Yasuo and Saburi, Masuho and Suehiro, Youko and Ogata, Masao and Kanda, Yoshinobu and Ishitsuka, Kenji and Atsuta, Yoshiko and Fuji, Shigeo},
  title = {Application Timing‐Dependent Impact of Donor Source on Outcomes After Allogeneic Hematopoietic Stem Cell Transplantation for Adult T‐Cell Leukemia/Lymphoma},
  journal = {Hematological Oncology},
  year = {2026},
  doi = {10.1002/hon.70220}
}
Kostenlos starten →